相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- The global wearable cardiac monitoring devices market was valued at USD 2.9 billion in 2025 and is projected to reach USD 10.3 billion by 2036, expanding at a CAGR of 12.1%. - The electrocardiography (ECG) technology segment dominated the market in 2025, accounting for approximately 62.1% of total revenue, driven by its clinical accuracy in detecting arrhythmias and atrial fibrillation. - North America held the largest regional share at 41.2% in 2025, supported by advanced healthcare infrastructure and growing adoption of remote patient monitoring solutions. - Rising prevalence of cardiovascular diseases and cardiac arrhythmias, coupled with growing demand for continuous, real-time cardiac monitoring, is the primary growth driver.
- The Philips-coordinated PreciseOnco consortium has been awarded €14.9 million in EU funding to develop integrated spectral imaging, robotic guidance, and AI technologies for minimally invasive cancer treatment. - The five-year research program will conduct five clinical studies across multiple cancer types to validate spectral imaging and robotic guidance systems with sub-millimeter precision. - The initiative addresses the growing cancer burden, with projections of over 35 million new cases globally by 2050, representing a 77% increase from 2022. - The consortium unites leading European hospitals, research organizations, and industry partners to standardize and enhance precision in interventional oncology procedures.
- The iMODERN trial, the largest global study to date using iFR technology in heart attack patients, found no significant difference in major outcomes between immediate and delayed treatment of additional narrowed arteries over three years. - The study enrolled 1,146 patients across 41 hospitals in 14 countries and was published in The New England Journal of Medicine, confirming both treatment approaches are equally safe and effective. - Complementary ILIAS ANOCA study results demonstrated that physiology-guided coronary function testing significantly improved angina symptoms and quality of life in patients with no obstructive coronary arteries. - These findings provide cardiologists with evidence-based flexibility to tailor treatment timing decisions for individual heart attack patients without compromising long-term outcomes.
- The FDA has granted 510(k) clearance to an updated version of the Philips UroNav System, featuring advanced annotation workflow for enhanced precision in minimally invasive prostate cancer focal therapy procedures. - The platform integrates pre-procedural MRI imaging with real-time intra-procedural ultrasound to provide clinicians with comprehensive visualization of target areas during treatment. - The system works in tandem with DynaCAD Urology to support focal therapy planning, delivery, and review, allowing urologists to edit prostate segmentation and add targets as needed. - Clinical experts highlight the platform's potential to personalize therapy with greater accuracy while sparing patients unnecessary side effects of traditional treatments.
